SAN FRANCISCO (AP) _ FibroGen Inc. (FGEN) on Thursday reported a loss of $42.6 million in its third quarter.
The San Francisco-based company said it had a loss of 50 cents per share.
The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 35 cents per share.
The biotech drug developer posted revenue of $29 million in the period, which also did not meet Street forecasts. Three analysts surveyed by Zacks expected $46.1 million.
FibroGen shares have dropped slightly more than 8 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $43.48, a drop of 20 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FGEN at https://www.zacks.com/ap/FGEN